Biogen (NASDAQ:BIIB) was downgraded to hold from buy by Jefferies, due in part to a looming royalty cut for the multiple sclerosis drug Ocrevus. Jefferies said it downgraded the stock on three ...

Ocrevus (ocrelizumab) is prescribed to treat certain forms of multiple sclerosis. The drug comes as a solution for intravenous (IV) infusion (into a vein). Ocrevus may not be safe to receive while ...

Roche ROG-0.70%decrease; red down pointing triangle confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and hemophilia injection Hemlibra ...

Ocrevus is Roche's best-selling drug and has been among the company's major growth drivers, with 2024 revenues up 9% at 6.7 billion Swiss francs ($7.59 billion).

Its bestseller Ocrevus gained 16% in sales to 1.52 billion francs during the quarter, while Hemlibra jumped 23% to 952 million francs, both excluding the effect of currency swings.

Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed ...

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ability ...

Roche Holding’s (NASDAQ:RHHBY) Ocrevus has been on a stellar run with sales exceeding $2.4 billion in 2018, reflecting a growth of 2.8x over the prior year. This can be attributed to its high ...

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis ...

The Ocrevus subcutaneous injection was shown to be non-inferior to the IV, as measured by pharmacokinetics (levels in the blood) over 12 weeks. The subcutaneous injection was also comparable in ...

Ocrevus Drug Analysis 2017: A Second-Generation Cluster of Differentiation (CD)20 Antibody - ResearchAndMarkets.com February 19, 2018 01:26 PM Eastern Standard Time ...